Find a Researcher
Junxiang Yin, PhD
Dr. Junxiang Yin received his MD and PhD degrees from Beijing University of Chinese Medicine in 2003 and has been working at Barrow Neurological Institute since 2009. He has more than 20 years of research experience with Stroke and Alzheimer’s disease.
As a highly skilled senior neuroscientist, the goal of his research is to develop preventive and therapeutic strategies for the treatment of stroke patients. He has developed novel methods of modelling human stroke in rodents including monofilament occlusion, ligation, photo thrombosis, and occlusion reperfusion. Currently, his research mainly focuses on the pathophysiological mechanism of neutrophil extracellular trap (NET) formation and promising neuroprotective strategies in Stroke.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
Date: 04/2023
Authors: Priya S. Kishnani, Jordi Diaz-Manera, Antonio Toscano, Paula R. Clemens, Shafeeq Ladha, Shafeeq S. Ladha, Kenneth I. Berger, Hani Kushlaf, Volker Straub, Gerson Carvalho, Tahseen Mozaffar, Mark Roberts, Shahram Attarian, Yin-Hsiu Chien, Young-Chul Choi, John W. Day, Sevim Erdem-Ozdamar, Sergey Illarioshkin, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Ans T. van der Ploeg, Kristina An Haack, Olivier Huynh-Ba, Swathi Tammireddy, Nathan Thibault, Tianyue Zhou, Mazen M. Dimachkie, Benedikt Schoser
Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.
Date: 03/2022
Authors: Kanchan Bhatia, Adam Kindelin, Muhammad Nadeem, Mohammad Badruzzaman Khan, Junxiang Yin, Alberto Fuentes, Karis Miller, Gregory H Turner, Mark C Preul, Abdullah S Ahmad, Elliott J Mufson, Michael F Waters, Saif Ahmad, S Ahmad, Andrew F Ducruet, A. F. Ducruet, Andrew F. Ducruet
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Date: 12/2021
Authors: Jordi Diaz-Manera, Priya S. Kishnani, Hani Kushlaf, Shafeeq Ladha, Shafeeq S. Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, Ans T. van der Ploeg, Kenneth I. Berger, Paula R. Clemens, Yin-Hsiu Chien, John W. Day, Sergey Illarioshkin, Mark Roberts, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Young Chul Choi, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Judith Johnson, Nathan Thibault, Tianyue Zhou, Mazen M. Dimachkie, Benedikt Schoser
Effect of ApoE isoforms on mitochondria in Alzheimer disease
Date: 06/2020
Authors: Junxiang Yin, Eric M. Reiman, Thomas G. Beach, Geidy E. Serrano, Marwan N. Sabbagh, M N. Sabbagh, Megan Nielsen, Richard J. Caselli, Jiong Shi
Apolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway
Date: 12/2019
Authors: Junxiang Yin, Megan Nielsen, Tanner Carcione, Shiping Li, Jiong Shi
Junxiang Yin, PhD
Dr. Junxiang Yin received his MD and PhD degrees from Beijing University of Chinese Medicine in 2003 and has been working at Barrow Neurological Institute since 2009. He has more than 20 years of research experience with Stroke and Alzheimer’s disease.
As a highly skilled senior neuroscientist, the goal of his research is to develop preventive and therapeutic strategies for the treatment of stroke patients. He has developed novel methods of modelling human stroke in rodents including monofilament occlusion, ligation, photo thrombosis, and occlusion reperfusion. Currently, his research mainly focuses on the pathophysiological mechanism of neutrophil extracellular trap (NET) formation and promising neuroprotective strategies in Stroke.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
Date: 04/2023
Authors: Priya S. Kishnani, Jordi Diaz-Manera, Antonio Toscano, Paula R. Clemens, Shafeeq Ladha, Shafeeq S. Ladha, Kenneth I. Berger, Hani Kushlaf, Volker Straub, Gerson Carvalho, Tahseen Mozaffar, Mark Roberts, Shahram Attarian, Yin-Hsiu Chien, Young-Chul Choi, John W. Day, Sevim Erdem-Ozdamar, Sergey Illarioshkin, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Ans T. van der Ploeg, Kristina An Haack, Olivier Huynh-Ba, Swathi Tammireddy, Nathan Thibault, Tianyue Zhou, Mazen M. Dimachkie, Benedikt Schoser
Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.
Date: 03/2022
Authors: Kanchan Bhatia, Adam Kindelin, Muhammad Nadeem, Mohammad Badruzzaman Khan, Junxiang Yin, Alberto Fuentes, Karis Miller, Gregory H Turner, Mark C Preul, Abdullah S Ahmad, Elliott J Mufson, Michael F Waters, Saif Ahmad, S Ahmad, Andrew F Ducruet, A. F. Ducruet, Andrew F. Ducruet
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Date: 12/2021
Authors: Jordi Diaz-Manera, Priya S. Kishnani, Hani Kushlaf, Shafeeq Ladha, Shafeeq S. Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, Ans T. van der Ploeg, Kenneth I. Berger, Paula R. Clemens, Yin-Hsiu Chien, John W. Day, Sergey Illarioshkin, Mark Roberts, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Young Chul Choi, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Judith Johnson, Nathan Thibault, Tianyue Zhou, Mazen M. Dimachkie, Benedikt Schoser
Effect of ApoE isoforms on mitochondria in Alzheimer disease
Date: 06/2020
Authors: Junxiang Yin, Eric M. Reiman, Thomas G. Beach, Geidy E. Serrano, Marwan N. Sabbagh, M N. Sabbagh, Megan Nielsen, Richard J. Caselli, Jiong Shi
Apolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway
Date: 12/2019
Authors: Junxiang Yin, Megan Nielsen, Tanner Carcione, Shiping Li, Jiong Shi